Home › merck
 

Keywords :   


Tag: merck

Merck Statement on FDA Advisory Committee Meeting for BRIDION (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium

2015-11-06 20:13:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION (sugammadex). BRIDION is the proposed trade name for Mercks investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or statement agent meeting

 

Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting

2015-11-05 14:43:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data present meeting annual

 
 

GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment

2015-11-03 12:58:00| Merck.com - Product News

Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSKs OX40 agonist GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSKs investigational immunotherapy GSK3174998 as monotherapy and in combination with Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment. Language: English Contact: MerckMedia Relations:Pamela Eisele, +1 267-305-3558orAn Phan, +1 908-255-6325orInvestor Relations:Justin Holko, +1 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study potential treatment combination

 

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Advanced Colorectal Cancer

2015-11-02 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced food administration drug

 

Merck And Pfizer Showing Significant Upside Potential From Increased Drug Sales Outlook

2015-10-29 16:49:19| Biotech - Topix.net

Merck and Pfizer are leading investment options in the pharmaceutical healthcare sector given the lower risk and higher return they offer investors over smaller capitalization stocks. Third quarter earnings for Merck and Pfizer showed significant potential for value gains as both drug manufacturers beat earnings expectations and increased their guidance for 2015 as a result of improving dynamics in the healthcare sector.

Tags: sales showing significant potential

 

Sites : [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] next »